Fengyan Jin
Clinical trials sponsored by Fengyan Jin, explained in plain language.
-
New combo therapy aims to control multiple myeloma after first return
Disease control Recruiting nowThis study looks at a combination of three drugs—daratumumab, pomalidomide, and dexamethasone (Dara-PD)—for people whose multiple myeloma has come back for the first time. The goal is to see how well this treatment controls the disease and delays further progression. About 50 adu…
Sponsor: FengYan Jin • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Tailored therapy may improve outcomes for frail elderly myeloma patients
Disease control Recruiting nowThis study tests a personalized treatment approach for people aged 65 and older who are newly diagnosed with multiple myeloma. The treatment plan is adjusted based on each patient's frailty level, aiming to improve response rates and reduce the chance of stopping treatment due to…
Sponsor: FengYan Jin • Aim: Disease control
Last updated May 01, 2026 15:57 UTC